Experimental Drug Combination Shows Promise in Reducing Acute Suicide Risk

Suicide is the 11th leading cause of death in the United States, claiming 48,824 lives in 2024 [1]. Another 2.2 million adults attempted suicide that year, and 14.3 million reported serious suicidal thoughts [1]. The U.S. suicide rate has climbed roughly 41% since 2000, from 10.1 per 100,000 people to 14.2 per 100,000 in 2021 [2].

Source: WHO Global Health Observatory

Data as of Dec 31, 2021CSV

Against that backdrop, a new trial published May 19, 2026 in the American Journal of Psychiatry has attracted widespread attention — and headlines — for showing that a two-step drug protocol can produce rapid and sustained reductions in suicidal ideation [3]. The combination: a single intravenous ketamine infusion followed by four weeks of low-dose buprenorphine. The results are real, but the study is small, the lead institution has a complicated history with opioid-adjacent research, and the gap between a promising Phase 2 signal and a treatment that reaches millions of patients is vast.

The Trial: Design, Doses, and Results

The study, led by Jason M. Tucciarone, M.D., Ph.D. and senior author Alan F. Schatzberg, M.D. at Stanford University, enrolled 50 adults with major depressive disorder and clinically significant suicidal ideation [3][4]. All participants first received a single open-label intravenous ketamine infusion. Two days later, they were randomized in a double-blind design to receive either low-dose buprenorphine or placebo for four weeks [3].

Of the 50 enrolled, 45 completed at least one week of follow-on treatment and were included in the primary analysis [4]. At week four, the buprenorphine group showed a 76% reduction in suicidal ideation, compared to a 43% reduction in the placebo group [3][4]. Depression scores improved in both groups, but the between-group difference on depression was not statistically significant [3].

"This is the second trial to indicate that buprenorphine at low doses reduces suicidal ideation in major depression," Schatzberg said. "However, unlike earlier reports, the degree of reduction was enhanced markedly by pretreating with intravenous ketamine" [5].

Specific dosing details, confidence intervals, and p-values for the primary endpoint were not available in the press coverage or study summaries at the time of publication. The study's DOI is 10.1176/appi.ajp.20250840 [4].

How This Compares to Existing Treatments

The psychiatric field has struggled for decades with a fundamental timing problem: the people most at risk of killing themselves cannot afford to wait weeks for conventional antidepressants to work.

Ketamine has been studied extensively as a rapid-acting intervention. A 2024 meta-analysis found it reliably reduces suicidal ideation within hours of infusion [6]. But the effect fades quickly — typically within days to a week [6]. Esketamine (Spravato), the nasal spray form approved by the FDA in 2020 for depressive symptoms in adults with MDD and suicidal thoughts, showed mixed results in Janssen's Phase 3 ASPIRE trials: more patients achieved resolution of suicidal ideation at 4 hours compared to placebo, but the difference was no longer statistically significant at 24 hours or 25 days [7].

The ketamine-buprenorphine protocol addresses this durability gap directly. By adding buprenorphine after the initial ketamine infusion, the Stanford team found the anti-suicidal effect was not only maintained but amplified over four weeks [3]. No 30-day or 90-day re-attempt rate data were reported, and the trial was not designed to measure suicide attempts as an endpoint — it tracked suicidal ideation using validated scales [4].

An earlier randomized controlled trial published in the American Journal of Psychiatry in 2016 had already shown that ultra-low-dose buprenorphine alone reduced suicidal ideation compared to placebo over two weeks [8]. The new study builds on that finding by combining it with ketamine's rapid-onset mechanism.

The Mechanism: Why Opioid Receptors Matter

Buprenorphine is a partial agonist at the mu-opioid receptor and a potent antagonist at the kappa-opioid receptor [9]. This dual action is central to the proposed mechanism.

The kappa-opioid system is implicated in dysphoria, anhedonia, and psychological pain. Dynorphin, the endogenous molecule that activates kappa receptors, has been found at elevated levels in the caudate putamen of suicide victims [9]. By blocking kappa receptors, buprenorphine may directly reduce the psychological anguish that drives suicidal thinking. Its partial mu agonism, meanwhile, activates reward circuitry without producing the full euphoria — or the full respiratory depression risk — of traditional opioids [9].

Ketamine's role is more complex. Traditionally understood as an NMDA receptor antagonist acting on the glutamate system, ketamine's mechanism was complicated by Schatzberg's own 2018 research. In that study, the opioid-blocking drug naltrexone completely prevented ketamine's antidepressant effects while leaving its dissociative effects intact — a finding so striking the trial was halted at interim analysis [10]. The implication: ketamine's antidepressant and anti-suicidal effects may depend substantially on opioid receptor activation, not just glutamate modulation [10].

This connects the two drugs mechanistically. If ketamine works in part by activating the opioid system, and buprenorphine sustains that activation through partial mu agonism while also blocking the dysphoria-producing kappa system, the combination targets what may be the same underlying neurobiology from two angles.

Source: OpenAlex

Data as of Jan 1, 2026CSV

Who Was Excluded — and What That Means

The trial excluded individuals with substance use disorders [4]. Given that buprenorphine is itself an opioid — most commonly used in clinical practice as a treatment for opioid addiction (branded as Suboxone or Subutex) — this exclusion is both understandable and consequential.

Co-occurring substance use disorders are common among people who attempt suicide. A 2019 study found that roughly 22% of people who died by suicide had evidence of substance use disorders [11]. Excluding this population from the trial means the findings cannot be generalized to a significant portion of the people most in need.

Other exclusion criteria were not detailed in available summaries. It is unclear whether the trial enrolled adolescents (unlikely, given standard practice in early-phase psychiatric trials), people with psychotic features, or those with active medical comorbidities. The sample of 50 adults at a single academic center is also not representative of the demographic and geographic diversity of suicidal patients across the country.

Adverse Effects and Abuse Potential

The study reported no serious treatment-related adverse events [3][4]. At low doses used for psychiatric indications — typically a fraction of what is prescribed for opioid use disorder — buprenorphine produces less euphoria, less physical dependence, and less withdrawal discomfort than full opioid agonists [9][12].

But "less" is not "none." Buprenorphine at any dose carries some dependence potential. Diversion and misuse do occur [12]. The study did not include extended follow-up to assess rebound suicidality after discontinuation — a critical gap, given that the very mechanism by which the drug may reduce suicidal thoughts (opioid receptor modulation) could theoretically produce withdrawal-related mood destabilization when stopped [8].

Ketamine carries its own risk profile: dissociation, elevated blood pressure, and potential for abuse. The FDA's Risk Evaluation and Mitigation Strategy (REMS) for esketamine already requires in-clinic administration with monitoring [13]. A combined ketamine-buprenorphine protocol would likely face similar or stricter oversight requirements.

The Replication Problem in Psychiatric Drug Trials

Psychiatric drug development has a well-documented history of promising early results that fail to replicate. Repeated, non-escalating doses of ketamine did not outperform placebo in a double-blind trial of patients with severe treatment-resistant depression and chronic suicidal ideation [7]. Multiple NMDA-receptor-targeting compounds have failed in Phase 3 after encouraging Phase 2 data.

Several methodological concerns apply to the current study:

Small sample size. With 50 enrolled and 45 analyzed, the trial is powered to detect large effects but could easily overestimate the true effect size — a well-known statistical phenomenon in small trials.

Open-label ketamine phase. All participants received ketamine before randomization, meaning both groups started from a ketamine-enhanced baseline. The placebo group's 43% improvement may partly reflect ketamine's lasting effects, natural recovery, or placebo response — all of which inflate the apparent baseline and complicate interpretation.

Placebo response in suicidal ideation. Research has shown that placebo response in suicidal ideation trials is substantial, with significant natural improvement observed by day three in some studies [7]. The therapeutic context of a clinical trial — including regular clinical contact, monitoring, and the knowledge that one might be receiving an active treatment — itself reduces suicidal thinking.

Surrogate endpoint. The trial measured suicidal ideation, not suicide attempts or deaths. Ideation is a risk factor for attempts, but the relationship is not one-to-one, and regulatory agencies have grown cautious about approving drugs on the basis of surrogate psychiatric endpoints alone.

Source: WHO Global Health Observatory

Data as of Dec 31, 2021CSV

Funding, Patents, and Conflicts of Interest

The trial was funded by the American Foundation for Suicide Prevention (AFSP), the Pritzker Foundation, the National Institute on Drug Abuse, and Stanford's Clinical and Translational Science Award Program [5]. Christine Yu Moutier, Chief Medical Officer of AFSP, called the combination "a potentially scalable and safe therapeutic option for patients at risk of suicide" [4].

Schatzberg's involvement warrants disclosure of his history. In 2008, Senator Charles Grassley investigated Schatzberg for failing to fully disclose the value of his holdings in Corcept Therapeutics, a company he co-founded to develop mifepristone for psychotic depression [14]. Schatzberg had reported stock holdings as "over $100,000" when their actual value exceeded $6 million [14]. He was simultaneously serving as principal investigator on a National Institute of Mental Health grant studying mifepristone — the same drug his company was developing [14][15]. He stepped down as PI on that grant under pressure.

This history does not invalidate the current study's findings. But it means those findings should be scrutinized with particular care, and independent replication by researchers without financial ties to the drugs involved is essential before drawing strong conclusions.

The current study does not appear to involve a proprietary drug combination — both ketamine and buprenorphine are available as generics — which reduces but does not eliminate potential commercial incentives. Patent filings related to the specific combination protocol or dosing sequence could create intellectual property positions even around generic drugs.

What FDA Approval and Deployment Would Look Like

If the ketamine-buprenorphine combination were to advance toward FDA approval, the path would be long and expensive. A Phase 3 trial would need hundreds or thousands of participants across multiple sites, with longer follow-up and harder endpoints than suicidal ideation scores.

For cost context: a single ketamine IV infusion currently runs $400 to $800 at U.S. clinics, with an initial course of six to eight sessions costing $2,400 to $6,400 [16]. Esketamine (Spravato) costs $590 to $885 per session without insurance, or roughly $4,700 to $7,000 for the first month [13]. Buprenorphine is available as a generic and relatively inexpensive — but the clinical infrastructure required for IV ketamine administration, monitoring, and follow-up adds substantial cost.

Insurance coverage would be a major barrier. Esketamine already faces frequent prior authorization denials on first submission, and many patients wait weeks or months for approval [13]. A novel, unapproved combination would face even steeper coverage hurdles until — and unless — it receives FDA indication.

The roughly 2.2 million Americans who attempt suicide each year, and the 14.3 million who experience serious suicidal thoughts, represent a population that the current mental health system already struggles to serve [1]. Even if the combination works as well in larger trials as it did in this one, deploying it at scale would require a massive expansion of clinical infrastructure — ketamine-certified facilities, trained providers, and monitoring protocols — that does not currently exist.

The Bottom Line

The ketamine-buprenorphine study is a legitimately interesting signal. A 76% reduction in suicidal ideation, sustained over four weeks, would be clinically meaningful if it holds up. The mechanistic rationale — targeting the opioid system's role in psychological pain — is grounded in a decade of research, including Schatzberg's own work demonstrating that ketamine's effects depend on opioid receptor activation.

But 50 patients is not enough to change clinical practice. The excluded populations — people with substance use disorders, likely adolescents, potentially those with psychotic features — are among those at highest risk. The lead researcher's conflict-of-interest history demands independent replication. And the distance from a single-site proof-of-concept trial to a treatment available at the scale of the American suicide crisis is measured in years and billions of dollars.

The study answers a scientific question about mechanism. It does not yet answer the clinical question of whether this treatment can save lives at scale — and the history of psychiatric drug development counsels patience before treating that question as resolved.